Start › Glejak wielopostaciowy › Nowy Jork › New York City
Badania kliniczne dla Glejak wielopostaciowy w mieście New York City, NY
30 badań dla Glejak wielopostaciowy szuka uczestników w ośrodkach w mieście New York City i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
RekrutacjaFaza 3
- Weill Cornell Medicine, New York
- NewYork-Presbyterian / Columbia University Irving Medical Center, New York
- Lennox Hill Hospital, New York
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RekrutacjaFaza 2
- New York University Langone's Perlmutter Cancer Institute, New York
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
RekrutacjaFaza 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RekrutacjaFaza 2/3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center*, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RekrutacjaFaza 2
- Columbia University Irving Medical Center, New York
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
RekrutacjaFaza 1
- Lenox Hill Hospital, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RekrutacjaFaza 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
RekrutacjaFaza 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RekrutacjaFaza 1/2
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RekrutacjaFaza 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekrutacjaFaza 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- i 1 więcej
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
RekrutacjaFaza 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RekrutacjaFaza 1
- NYU Langone Health, New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Rekrutacja
- NYU Langone Health, New York
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
RekrutacjaFaza 2
- New York Langone, New York
- Columbia University, New York
- Memorial Sloan Kettering Cancer Center, New York
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RekrutacjaFaza 2
- Lenox Hill Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RekrutacjaFaza 1/2
- Lenox Hill Brain Tumor Center, New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RekrutacjaFaza 3
- Lenox Hill Brain Tumor Center, New York
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
RekrutacjaFaza 1/2
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Rekrutacja
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Rekrutacja
- Lenox Hill Brain Tumor Center, New York
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RekrutacjaFaza 1/2
- Lenox Hill Brain Tumor Center, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekrutacjaFaza 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RekrutacjaFaza 2
- Lenox Hill Brain Tumor Center, New York
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RekrutacjaFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, New York
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RekrutacjaFaza 1
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Badania dla Glejak wielopostaciowy w innych miastach
- Boston, MA28 badań
- Houston, TX26 badań
- Los Angeles, CA24 badań
- Durham, NC20 badań
- San Francisco, CA17 badań
- Chicago, IL15 badań
- Washington, DC15 badań
- Miami, FL14 badań
- Columbus, OH14 badań
- Rochester, MN13 badań
- Jacksonville, FL13 badań
- Aurora, CO12 badań
Inne badania w mieście New York City
- Rak piersi136 badań
- Niedrobnokomórkowy rak płuca121 badań
- Nowotwory (wszystkie typy)109 badań
- Rak prostaty103 badań
- Nowotwór przerzutowy93 badań
- Rak jelita grubego i odbytnicy78 badań
- Rak jajnika69 badań
- Rak płuc60 badań
- Szpiczak mnogi60 badań
- Rak trzustki60 badań
- Rak endometrium52 badań
- Ostra białaczka szpikowa51 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.